A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3427299 ◽

2019 ◽

Author(s):

Brian Rini ◽

Sumanta K. Pal ◽

Bernard J. Escudier ◽

Michael B. Atkins ◽

Thomas E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30735-1 ◽

2020 ◽

Vol 21 (1) ◽

pp. 95-104 ◽

Cited By ~ 22

Author(s):

Brian I Rini ◽

Sumanta K Pal ◽

Bernard J Escudier ◽

Michael B Atkins ◽

Thomas E Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Randomised Controlled

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

European Journal of Cancer ◽

10.1016/j.ejca.2018.11.001 ◽

2019 ◽

Vol 107 ◽

pp. 37-45 ◽

Cited By ~ 4

Author(s):

Margitta Retz ◽

Jens Bedke ◽

Martin Bögemann ◽

Marc-Oliver Grimm ◽

Uwe Zimmermann ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Annals of Translational Medicine ◽

10.21037/atm.2020.03.217 ◽

2020 ◽

Vol 8 (16) ◽

pp. 1037-1037

Author(s):

Mary E. Westerman ◽

Christopher G. Wood

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Editorial Commentary ◽

Randomised Controlled

Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)

Annals of Oncology ◽

10.1093/annonc/mdx371 ◽

2017 ◽

Vol 28 ◽

pp. v295 ◽

Cited By ~ 13

Author(s):

M. Retz ◽

J. Bedke ◽

E. Herrmann ◽

M-O. Grimm ◽

U. Zimmermann ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps4578 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4578-TPS4578 ◽

Cited By ~ 19

Author(s):

Hans J. Hammers ◽

Elizabeth R. Plimack ◽

Cora Sternberg ◽

David F. McDermott ◽

James M. G. Larkin ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Iii ◽

Open Label ◽

Open Label Study ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Randomised Controlled Trial ◽

Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-005-0070-z ◽

2005 ◽

Vol 57 (4) ◽

pp. 533-539 ◽

Cited By ~ 38

Author(s):

Monika Jermann ◽

Rolf A Stahel ◽

Marc Salzberg ◽

Thomas Cerny ◽

Markus Joerger ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Locally Advanced ◽

Open Label ◽

Open Label Study ◽

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2013.11.007 ◽

2014 ◽

Vol 12 (3) ◽

pp. 167-177.e2 ◽

Cited By ~ 19

Author(s):

David S. Hong ◽

Michael S. Gordon ◽

Wolfram E. Samlowski ◽

Razelle Kurzrock ◽

Nizar Tannir ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Open Label Study ◽

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70030-0 ◽

2014 ◽

Vol 15 (3) ◽

pp. 286-296 ◽

Cited By ~ 177

Author(s):

Robert J Motzer ◽

Camillo Porta ◽

Nicholas J Vogelzang ◽

Cora N Sternberg ◽

Cezary Szczylik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Targeted Treatment ◽

Open Label ◽

Phase 3 ◽

Third Line